Bioneer Corporation (064550) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bioneer Corporation KRW 3,547, price KRW 8,180, upside -56.6%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bioneer Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 5,790 KRW – 93,200 KRW · fair‑value band 2,042 KRW – 5,898 KRW · the 8,180 KRW price screens above the 3,547 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bioneer in your weekly email
Every Wednesday you see whether Bioneer is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea.
Show more
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.
Stock analysis
Bioneer Corporation (064550) currently trades at 8,180 KRW, while our model-based Fair Value estimate is 3,547 KRW, implying the stock looks roughly 130.6% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 10,316 KRW per share, and 6 of the 12 models we run sit above the 8,180 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,996 KRW, and 6 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: 2,042 KRW (bear) to 5,898 KRW (bull), the price of 8,180 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bioneer Corporation reported revenue of 330B KRW in FY2025 versus 224B KRW in FY2021, a compound +10.2%/yr. Reported net income was −2.8B KRW in FY2025.
Key figures
Market cap 211B KRW (≈ $148M) · P/S ratio 0.71 · Net margin −0.9% · Return on equity −911% · Return on assets (EBIT) 4.4% · Operating margin 9.3% · Revenue (TTM) 224B KRW · Revenue growth (YoY) −14.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −32% fair-value upside, at −57%, 064550 screens richer than that median.
Fair Value models
Bear 2,042 KRWFair Value 3,547 KRWBull 5,898 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +31.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
50.2% (2020) → 4.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+45.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +42.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2614 stocks
Beats the sector median on 5/8 measures
Overall it ranks above its sector peers.
Valuation
Quality Score58 · Above median
Fair Value upside−23% · Below median
Profitability
Return on assets5% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)9% · Above median
Growth and dividend
Revenue growth−15% · Bottom 25%
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 13
HEALTH (low debt)86· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bioneer Corporation Fair Value". https://www.fairvalue-calculator.com/stock/064550
Frequently asked questions
Is Bioneer Corporation (064550) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,547 KRW versus a price of 8,180 KRW, about −57% upside (overvalued).
What is the fair value of 064550?
Our model-based fair value for Bioneer Corporation is 3,547 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,180 KRW.
What is the quality score of 064550?
Bioneer Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioneer Corporation (064550)?
Our model-based price target is the fair value of 3,547 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 2,042 KRW, optimistic scenario 5,898 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioneer Corporation stock forecast for 2026?
Our models put fair value at 3,547 KRW, about −57% upside versus a price of 8,180 KRW (overvalued). Cautious scenario 2,042 KRW, optimistic scenario 5,898 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Bioneer Corporation (064550)?
Bioneer Corporation reported trailing-twelve-month revenue of about 224B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Bioneer Corporation (064550)?
For today's price to be fair in a discounted-cash-flow model, Bioneer Corporation would have to grow free cash flow by +45.0 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 064550 use?
Our models discount Bioneer Corporation at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bioneer Corporation that is +45.0 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Bioneer Corporation (064550) delivered so far?
Over the past 5 years revenue at Bioneer Corporation grew +9.8 % a year. The price currently implies +45.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bioneer Corporation (064550) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bioneer Corporation (+45.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bioneer Corporation (064550)?
The free-cash-flow yield on the price is 1.50 %: that much free cash flow Bioneer Corporation produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bioneer Corporation (064550)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioneer Corporation it is 3,547 KRW per share (as of Sep 24, 2026), against a price of 8,180 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Bioneer Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 064550 trades above its calculated fair value: price 8,180 KRW, fair value 3,547 KRW, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 064550?
No. The price is what the market pays today (8,180 KRW); the fair value is what the company's own numbers justify (3,547 KRW). For Bioneer Corporation the two are 4,633 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioneer Corporation worth?
The market values Bioneer Corporation at about 211B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,180 KRW; our models calculate a fair value of 3,547 KRW per share.
What do the bullish and bearish scenarios say about 064550?
Our models span a range for Bioneer Corporation: cautious scenario 2,042 KRW, base 3,547 KRW, optimistic 5,898 KRW per share (as of Sep 24, 2026, price 8,180 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioneer Corporation (064550)?
Balance-sheet figures for Bioneer Corporation (as of Sep 24, 2026): debt of 0.29 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 064550 from its 52-week high?
Bioneer Corporation trades at 8,180 KRW, about 47% below its 52-week high of 15,500 KRW and 41% above the low of 5,790 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,547 KRW is for.
Which stocks are comparable to Bioneer Corporation?
From the same area (Healthcare) we also value MEDIPOST Co, Macrogen, Inc, Cell Biotech Co, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioneer Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 8,180 KRW, calculated fair value 3,547 KRW (−57%), Quality Score 58/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 064550 calculated?
We run Bioneer Corporation through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,547 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bioneer Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioneer Corporation (064550)?
The closing price on Sep 23, 2026 was 8,180 KRW. Our model-based fair value is 3,547 KRW, about −57% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioneer Corporation right now?
The price sits above even our optimistic bull case (5,898 KRW). The favourable scenario is already priced in. The model range is unusually wide (2,042 KRW to 5,898 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Bioneer Corporation
How large is the market capitalisation of Bioneer Corporation (064550)?
The market capitalisation of Bioneer Corporation is 211B KRW (≈ $148M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bioneer Corporation (064550)?
The price-to-sales ratio of Bioneer Corporation is 0.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Bioneer Corporation (064550)?
The net margin of Bioneer Corporation is −0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bioneer Corporation (064550)?
The return on equity (ROE) of Bioneer Corporation is −911% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioneer Corporation (064550)?
On an EBIT basis the return on assets of Bioneer Corporation is 4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioneer Corporation (064550)?
The operating margin of Bioneer Corporation is 9.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioneer Corporation (064550)?
Revenue at Bioneer Corporation is growing −14.7% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Bioneer Corporation (064550) carry?
The net debt of Bioneer Corporation is 56.8B KRW (fiscal year 2025, ≈ 17.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bioneer Corporation in the live analysis
One click puts Bioneer Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
